Coherus BioSciences, Inc.

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

Tue, 02 Feb 2021 13:30 GMT

REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.??

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada

Mon, 01 Feb 2021 10:30 GMT

- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody
- First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation
- Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential
- Conference call at 8:00 am Eastern Time today

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 22 Jan 2021 21:01 GMT

REDWOOD CITY, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares of the common stock of the Company to 3 newly hired non-officer employees, with a per share exercise price of $17.99, the closing trading price on the grant date.

Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors

Thu, 07 Jan 2021 21:01 GMT

REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021.?

Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference

Tue, 05 Jan 2021 21:01 GMT

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39^th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST.

Coherus BioSciences Announces New Employment Inducement Grants

Mon, 21 Dec 2020 21:02 GMT

REDWOOD CITY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 66,000 shares of the common stock of the Company to 5 newly hired non-officer employees, with a per share exercise price of $17.78, the closing trading price on the grant date.

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 20 Nov 2020 21:01 GMT

REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 140,500 shares of the common stock of the Company to 10 newly hired non-officer employees, with a per share exercise price of $17.92, the closing trading price on the grant date.

Coherus BioSciences Reports Third Quarter 2020 Financial Results

Thu, 05 Nov 2020 21:02 GMT

– Third Quarter UDENYCA? Net Sales of $113.6 Million –
– Net Income of $27.9 Million –
– Non-GAAP Net Income of $39.7 Million –

Coherus BioSciences to Report Third Quarter Financial Results on November 5th

Thu, 22 Oct 2020 20:15 GMT

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 16 Oct 2020 13:30 GMT

REDWOOD CITY, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 15, 2020, the compensation committee of the Company’s board of directors granted a newly hired Executive Vice President an option to buy 150,000 shares of the Company’s common stock with a per share exercise price of $18.09, the closing trading price on the grant date, and 10,000 restricted stock units.

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 18 Sep 2020 15:02 GMT

REDWOOD CITY, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective September 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 118,000 shares of the common stock of the Company to six newly hired non-officer employees, with a per share exercise price of $19.07, the closing trading price on the grant date.

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 21 Aug 2020 13:30 GMT

REDWOOD CITY, Calif., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 19, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,000 shares of the common stock of the Company to seven newly hired non-officer employees, with a per share exercise price of $19.85, the closing trading price on the grant date.

Coherus BioSciences Reports Second Quarter 2020 Financial Results

Thu, 06 Aug 2020 20:02 GMT

– Second Quarter UDENYCA^? Net Sales of $135.7 Million –
– Net Income of $59.0 Million –
– Non-GAAP Net Income of $68.3 Million –

Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors

Mon, 03 Aug 2020 20:48 GMT

REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020.?

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 17 Jul 2020 13:30 GMT

REDWOOD CITY, Calif., July 17, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 16, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 53,000 shares of the common stock of the Company to four newly hired non-officer employees, with a per share exercise price of $18.30, the closing trading price on the grant date.

Coherus BioSciences to Report Second Quarter Financial Results on August 6th

Thu, 16 Jul 2020 13:30 GMT

REDWOOD CITY, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released after market close on Thursday, August 6, 2020. Starting at 4:30 p.m. ET, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.?

Coherus BioSciences Announces New Employment Inducement Grants

Fri, 19 Jun 2020 13:30 GMT

REDWOOD CITY, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 93,000 shares of the common stock of the Company to seven newly hired non-officer employees, with a per share exercise price of $16.98, the closing trading price on the grant date.

Coherus BioSciences Reports First Quarter 2020 Financial Results

Thu, 07 May 2020 20:08 GMT

– First Quarter UDENYCA? Net Sales of $116.2 Million –
–Net Income of $35.6 Million –
– Non-GAAP Net Income of $49.8 Million –

Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference

Mon, 04 May 2020 13:30 GMT

REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET.

Coherus BioSciences to Report First Quarter Financial Results on May 7th

Wed, 22 Apr 2020 13:30 GMT

REDWOOD CITY, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020. Starting at 4:30 p.m. ET, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.?